Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes.
Hirulog therapy has been studied extensively in numerous settings including prevention of DVT, treatment of unstable angina, treatment of acute myocardial infarction during thrombolysis, and prevention of acute complications of PTCA. Being one of the first direct thrombin inhibitors in clinical development, it has had to 'test the waters', so to speak, of the relationship between pathophysiology and clinical trial design: what are the correct indications, patient entry criteria, endopoints, frequency and duration of dosing, and so on? Our findings validate a role for thrombin in treating arterial thromboembolism and demonstrate clinical activity and tolerability of Hirulog.
Biogen, Inc., Cambridge, Massachussetts, USA.
J M
JM
Maraganore
B A
BA
Adelman
D000208:Acute Disease; D000991:Antithrombins / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013577:Syndrome; D013924:Thrombophlebitis / Q000097:blood / Q000517:prevention & control
D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; C074619:bivalirudin